Demystifying Medicine Video



This video provides information about a novel pharmaceutical method PCSK9 injections that can be used to reduce the risks of familial hypercholesterolemia. The video outlines the mechanisms, benefits and costs, as depicted in scientific literature, of PCSK9 use in individuals who need to manage their cholesterol. The video does not intend to promote any specific PCSK9 inhibitors and acts to compare PCSK9 inhibitors to other treatment options, such as statins.

[Please complete our feedback form]




References
  • Fala, L. (2016). Repatha (Evolocumab): second PCSK9 inhibitor approved by the FDA for patients with familial hypercholesterolemia. American Health & Drug Benefits, 9, 136.
  • Paquette, M., & Baass, A. (2018). A novel cause of familial hypercholesterolemia: PCSK9 gene duplication. Canadian Journal of Cardiology, 34(10), 1259–1260. doi: 10.1016/j.cjca.2018.08.027
  • Sabatine, M. S., Ferrari, G. M. D., Giugliano, R. P., Huber, K., Lewis, B. S., Ferreira, J., …Pedersen, T. R. (2018). Clinical benefit of evolocumab by severity and extent of coronary artery disease. Circulation, 138(8), 756–766. doi: 10.1161/circulationaha.118.034309
  • Stroes, E., Colquhoun, D., Sullivan, D., Civeira, F., Rosenson, R. S., Watts, G. F., ... & Xue, A. (2014). Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. Journal of the American College of Cardiology, 63(23), 2541-2548. doi:10.1016/j.jacc.2014.03.019
  • Watson, K. E. (2019). Pitavastatin: the newest HMG-CoA reductase inhibitor. Reviews in Cardiovascular Medicine, 11(1), 26-32. doi:10.3909/ricm0535
  • Whayne, T. F. (2008). A viewpoint on statin effects–benefits and problems. International Journal of Angiology, 17(4), 178-180.
  • Zimmerman, M. P. (2015). How do PCSK9 inhibitors stack up to statins for low-density lipoprotein cholesterol control? American Health & Drug Benefits, 8(8), 436.